Genmab revenue and financials
Secondary listing. The primary listing is Genmab · Nasdaq Copenhagen (DKK)
$35.86Change from previous close: +3.18%Absolute change: +$1.10
In the fiscal year ended December 2025, Genmab reported revenue of kr 3.72B (+19.19% year over year). Net income was kr 963M, a net margin of 25.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +19.19%
- 2025 vs 2024
- Net income growth
- −87.72%
- 2025 vs 2024
- Net margin
- 25.9%
- 2024: 251.3%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Total revenue | 3,720 | 3,121 | 2,390 | 5,366 | 3,025 | 2,365 |
| Cost of revenue | 238 | 143 | 33.0 | — | — | — |
| Gross profit | 3,482 | 2,978 | 2,357 | — | — | — |
| Selling, general and administrative | 626 | 549 | 478 | — | — | — |
| Research and development | 1,606 | 1,414 | 1,107 | 2,386 | 1,431 | 874 |
| Operating income | 1,065 | 972 | 772 | 2,638 | 1,380 | 1,344 |
| EBIT | 1,265 | 1,344 | 827 | — | — | — |
| EBITDA | 1,336 | 1,404 | 870 | — | — | — |
| Interest expense | 269 | 291 | 254 | 7.0 | 11.0 | 352 |
| Pre-tax income | 1,204 | 1,326 | 817 | — | — | — |
| Income tax | 241 | 193 | 186 | 693 | 140 | -40.0 |
| Net income | 963 | 7,844 | 631 | 2,166 | 1,472 | 1,104 |
| Net income to common shareholders | 963 | 1,133 | 631 | — | — | — |
| Basic EPS | 15.50 | 122.21 | 66.64 | 34.40 | 24.03 | 18.14 |
| Diluted EPS | 15.37 | 17.53 | 9.58 | 34.03 | 23.73 | 17.77 |
| Average shares (basic) | 622 | 642 | 653 | — | — | — |
| Average shares (diluted) | 627 | 646 | 659 | — | — | — |